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Genetic and antigenic variation may be one means by which lentiviruses that cause AIDS avoid elimination
by host immune responses. Genetic variation in the envelope gene (env) was studied by comparing the
nucleotide sequences of 27 clones obtained from two rhesus monkeys infected with molecularly cloned simian
immunodeficiency virus. All 27 clones differed from each other and differed from the input clone in the gpl20
(SU) portion of the envelope gene. Nucleotide substitutions were shown to accumulate with time at an average
rate of 8.5 per 1,000 per year in SU. Surprisingly, the majority of nucleotide substitutions (81%) resulted in
amino acid changes. Variation in SU was not random but occurred predominantly in five discrete regions.
Within these variable regions, a remarkable 98 % of the nucleotide substitutions changed the amino acid. These
results demonstrate that extensive sequence variability accumulates in vivo after infection with molecularly
cloned virus and that selection occurs in vivo for changes in distinct variable regions of env.
Simian immunodeficiency virus (SIV) is a member of the
lentivirus subfamily of retroviruses. This group also includes
human immunodeficiency virus (HIV), equine infectious
anemia virus, visna virus, and caprine arthritis-encephalitis
virus. Members of the lentivirus subfamily establish longterm, persistent infections resulting in chronic, nononcogenic, debilitating disease.
Antigenic variation during persistent infection has been
documented for equine infectious anemia virus (27, 35),
visna virus (2, 38), and caprine arthritis-encephalitis virus
(7). Equine infectious anemia, in particular, is characterized
by recurrent clinical episodes of fever, hemolytic anemia,
bone marrow depression, lymphoproliferation, immune
complex glomerulonephritis, and persistent viremia (27).
Virus neutralization assays have shown that plasma recovered from an infected animal can effectively neutralize virus
isolated from earlier febrile episodes but cannot neutralize
virus isolates recovered during subsequent febrile episodes
(27, 35). Antigenic variation is thus one mechanism that
lentiviruses may use to evade the host immune system. In
previous studies of antigenic variation with the ungulate
lentiviruses, plaque-purified virus was not always used.
Molecularly cloned virus was never used in these previous
studies, and the genetic changes contributing to antigenic
variation have not been documented. Furthermore, the
ungulate lentiviruses are quite distant from HIV, and it is
difficult to extrapolate the significance of findings in these
systems to AIDS in humans. The SIVs are the closest known
relatives of the HIVs, and they share with their human
counterparts extensive similarity in genetic and biological
properties (for reviews, see references 4 and 8).
Comparison of the nucleotide sequences of SIV, HIV type
1 (HIV-1), and HIV-2 has revealed extensive genomic variability among these primate lentiviruses, particularly in the
envelope regions (see sequences in GenBank). Studies with
sequential isolates of HIV-1 have demonstrated heterogeneity within virus isolated at any one time and fluctuations
among virus populations over time in infected individuals
*

(10, 26, 34, 42). One question which arises from these studies
is whether such heterogeneity is generated by rapid evolution of HIV-1 over time in infected individuals or whether
such diversity may have been originally present in the
infecting virus inoculum. Studies on sequential isolates of
HIV-1 are usually complicated further by lack of information
on the time of infection in these individuals, making precise
measurement of nucleotide substitution rates impossible in
this system. Characterization of the precise rate and nature
of nucleotide substitutions is best made by using molecularly
cloned virus of known sequence in an experimental animal
model system in which the exact time of infection is known.
In this report we describe the study of envelope gene
variation in rhesus monkeys infected with the molecularly
cloned virus SIVmac239. We have documented the extent to
which genetic changes accumulate in env with time of in vivo
infection and have characterized the nature of the nucleotide
substitutions. Our results show that molecularly cloned SIV
rapidly evolves into a complex mix of genotypes during
infection of a single individual. The data further suggest that
variation in five discrete segments results from selective
forces operating in vivo. The host immune response is likely
to be a major source of this selective pressure.
MATERIALS AND METHODS

Virus. The SIVmac239 pathogenic molecular clone and its
complete sequence have been described previously (18, 19,
28, 30a).
Cells and cell lines. Macaque peripheral blood lymphocytes were obtained from blood samples collected in preservative-free heparin by banding over sodium diatrizoate-Ficoll
(1.077 to 1.080 g/ml at 20°C; Organon Teknika Corp.,
Durham, N.C.). Peripheral blood lymphocytes were stimulated with 1 ,ug of phytohemagglutinin per ml for 48 h,
washed free of lectin, and incubated in RPMI 1640 with 10%
fetal calf serum, interleukin-2 (lectin-free T-cell growth
factor; Electro-Nucleonics, Inc., Fairfield, N.J.), penicillin,
and streptomycin. Continuously growing human CD4+ cell
lines HuT 78 and CEM x 174 (16) were grown in RPMI 1640
medium with 10% fetal calf serum.
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Experimental infection of rhesus monkeys. Two juvenile
rhesus macaques (Macaca mulatta) previously negative for
SIV antibody were selected from the New England Regional
Primate Research Center colony. Rhesus macaque number
243-86 (Mm243-86) was inoculated intravenously on 4 August 1987 with 1 ml of virus derived from transfection of
molecularly cloned SIVmac239 into HuT 78 cells (28). The
virus was grown in HuT 78 cells for 41 days and had 29,592
cpm of reverse transcriptase activity per ml on the day of
inoculation. Mm326-87 was inoculated intravenously on 1
June 1989 with 1 ml of virus derived from transfection of
molecularly cloned SIVmac239 into rhesus macaque peripheral blood lymphocytes. The virus was grown in macaque
peripheral blood lymphocytes for 18 days and had 100,000
cpm of reverse transcriptase activity per ml on the day of
inoculation. Cell-free virus stocks for inoculation were prepared by centrifugation of infected cell cultures and filtration of viral supernatants through 0.45-,um- pore-size filters.
Heparinized blood samples were collected from the macaques at intervals after the virus inoculation and were used
for preparation of total cell DNA, for virus recovery, and for

monitoring antibody response.
DNA preparation. Total cell DNA (36) was prepared from
peripheral blood mononuclear cells (PBMCs) obtained at 69
and 93 weeks postinfection and from a lymph node biopsy
taken at 69 weeks from Mm243-86. A fraction of the lymph
node taken at 69 weeks and the PBMCs taken at 93 weeks
each cocultivated with CEM x 174 cells for 51 and 41
days, respectively, and cells infected with recovered virus
were used to prepare Hirt supernatant DNA (14). A fraction
of a 6-week PBMC sample from Mm243-86 was cocultivated
with HuT 78 cells for 68 days, and cells infected with
recovered virus were also used to prepare Hirt supernatant
DNA. For the control clones, the virus stock used to
inoculate Mm243-86 was used to infect HuT 78 cells, and
Hirt supernatant DNAs were prepared 31 and 55 days later.
From Mm326-87, total cell DNA was prepared at 43 weeks
postinfection from a PBMC sample.
PCR amplification. Total cell and Hirt supernatant DNAs
were used as templates in a polymerase chain reaction (PCR)
to specifically amplify full-length env sequences between
nucleotides 6544 and 9249 (numbering system of Regier and
Desrosiers [30a]). Because the copy number of SIV DNA
was much lower in blood and lymph nodes than in cells
infected with the recovered virus, it was necessary to
perform two rounds of PCR amplification for blood and
lymph node samples to obtain sufficient quantities of DNA
for cloning (PCR amplification method adapted from reference 39). One round of PCR refers to 30 cycles of amplification. The first round of PCR was performed with an outer
set of oligonucleotide primers (nucleotides 6474 through
6493, 5'-AGTGTTGCTACCATTGCCAG-3'; nucleotides 9279
through 9298, 5'-AGCTGGGTTTCTCCATGGAG-3'), whereas the second round was performed with a second set of
primers (nucleotides 6544 through 6573, 5'-GAGAAGAAGA
were

GCTCCGAAAAAGGCTAAGGC-3'; nucleotides 9220
through 9249, 5'-TGTCCCTCACAAGAGAGTGAGCTCAA
GCCC-3') complementary to the amplified product of the
first round. The second set of primers contained SstI sites
(underlined) for cloning; an A--G mutation was made in the
primer from nucleotides 6544 through 6573 at position 6554
to create one of the SstI sites. By using two sets of primers,
nonspecific amplification was reduced. By using two rounds
of PCR, the level of amplification was greatly increased. For
the Hirt supernatant DNA, only one set of primers was used
(nucleotides 6544 through 6573 and 9220 through 9249) in one
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round of PCR. One microgram of PBMC or lymph node
DNA or an empirically determined quantity of Hirt supernatant DNA was added to a PCR reaction containing the
following: 1.5 mM Mg2", 200 ,uM each dinucleoside triphosphate, 0.2 ,uM each oligonucleotide primer, and 2.5 U of Taq
polymerase. The total reaction volume of 100 [I was overlaid with light mineral oil. DNA was amplified for 30 cycles
with the following cycle profile: denaturation at 94°C for 1
min, annealing at 55°C for 2 min, and extension at 72°C for 3
min. An auto extension of 10 s was added to each PCR cycle,
and a 10-min final extension at 72°C was added to the last
cycle. PCR contamination was avoided by taking precautions similar to those outlined by Kwok and Higuchi (20). In
addition, negative DNA samples prepared simultaneously
with positive DNA samples were amplified in each PCR
experiment as controls, along with controls containing only
the reagent (no template DNA added).
Molecular cloning. Approximately 5% of each PCR reaction was analyzed on 1.0% agarose gels. The DNA was
transferred to nitrocellulose filters (Schleicher & Schuell,
Inc.) and hybridized with the gel-purified, 32P-labeled SstI
fragment (env) of SIVmac239. The remaining 95% of the
PCR reaction was precipitated with ethanol and digested
with SstI. Gel purification of the SstI fragment was necessary only for the 6-week Hirt supernatant DNA from
Mm243-86 due to a higher amount of nonspecific DNA in this
sample. After digestion with SstI, the PCR-amplified material was ligated with the SstI-cleaved vector pBS- (Stratagene). Approximately 25% of each ligation was used to
transform Escherichia coli XL1-Blue competent bacterial
cells (Stratagene). The F' episome of XL1-Blue contains the
lacPqZAM15 mutation providing ai-complementation of the
3-galactosidase gene for blue/white color selection. Single
white colonies were picked and screened by a colony hybridization method employing the envelope-specific, gelpurified SstI fragment of SIVmac239. Positive colonies were
selected for small-scale plasmid preparations, and clones
containing the desired 2.7-kbp insert were finally selected for
large-scale plasmid preparations and sequence analysis.
DNA sequencing. The double-stranded plasmid clones
were sequenced by the primer-directed dideoxy-chain termination method (37) with Sequenase (United States Biochemical Corp.) and a series of internal primers synthesized on a
Cyclone DNA synthesizer (Biosearch, Inc.). 35S-labeled
sequencing reactions were electrophoresed on 6% polyacrylamide gels with 8 M urea. Sequences were analyzed with
IBI-Pustell DNA analysis software.
Nucleotide sequence accession number. The nucleotide
sequences (data not shown) of the 27 clones from Mm243-86
and Mm326-87 and the 5 control clones have been filed with
GenBank under accession no. M61062 through M61093.
RESULTS
Infection of rhesus monkeys with molecularly cloned virus.
Two juvenile rhesus monkeys (Mm243-86 and Mm326-87)
were inoculated intravenously with virus derived from transfection of molecularly cloned SIVmac239. The SIVmac239
clone is known to yield virus that causes AIDS in rhesus
monkeys (18), and its complete sequence is known (30a). A
persistent infection was established in both animals, since
SIV was repeatedly isolated from their blood over time. The
animals also developed strong stable antibody responses to
SIV as measured by enzyme-linked immunosorbent assays,
Western immunoblots, and neutralization assays (data not
shown). Mm243-86 was euthanatized when death appeared
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imminent after persistent infection with SIV for 2.9 years.
Mm326-87 is presently asymptomatic 1.2 years after infection.
Using the PCR amplification and cloning strategy described in Materials and Methods, 98 full-length env clones
were obtained from PBMCs, lymph node tissue, and cells
infected with recovered virus at 6, 69, and 93 weeks postinfection from Mm243-86. At the time these clones were
obtained, Mm243-86 was asymptomatic. By using the same
procedures, 13 full-length env clones were obtained from
Mm326-87 from a 43-week PBMC sample. The DNA sequences of SU of 21 clones from Mm243-86 and 6 clones
from Mm326-87 were determined. This represents 42,406 bp
of sequence information from these two animals.
Variable regions of the SIV envelope. The translated amino
acid sequences of the 22 late-time-point clones from
Mm243-86 and Mm326-87 revealed a total of five variable
regions in the gp120 region of env (Fig. 1 and 2). Variable
regions 1 and 2 were located near the amino terminus of
gp120 between amino acids 115 and 142 and between amino
acids 188 and 202, respectively. Variable region 3 was
located between amino acid residues 371 and 376, between
the regions corresponding to the variable cysteine loop (40)
and the CD4 binding domain (21) of HIV-1. Variable regions
4 and 5 were found immediately flanking the region corresponding to the CD4 binding domain of HIV-1 between
amino acid residues 404 and 426 and between residues 473
and 478, respectively.
In addition to the five variable regions in gp120, there was
also a variable region in the signal peptide of late-time-point
clones from Mm243-86 (Fig. 1). In late-time-point clones
from both Mm243-86 and Mm326-87, there was also selection for particular amino acid changes at several points in
gpl20. There was selection for glutamine at amino acid
residue 24, methionine at residue 67, and glycine and asparagine at residue 511 (Fig. 1 and 2).
Variable regions V2, V3, V4, and V5 are located at
potential sites of N-linked glycosylation (N-X-T or N-X-S),
whereas Vl is immediately adjacent to a potential N-linked
glycosylation site. Within variable region 4, an alanine-tothreonine change in 21 of 22 late-time-point clones resulted
in the creation of a new potential N-linked glycosylation site
(Fig. 1 and 2).
Two of the late-time-point clones (T69 BL 1-21 in Fig. 1
and T43 BL 20-8 in Fig. 2) had deletions in variable region 1.
Both deletions were two amino acids in length, did not
change the reading frames, and were located in slightly
different locations in the two clones. Half of the late-timepoint clones from Mm243-86 had deletions in variable region
4, and the deletions were found in clones obtained from
PBMCs and lymph nodes as well as recovered virus. Three
different lengths of deletions were observed (Fig. 1). Since
none of the deletions changed the reading frame, we suspect
that most of these deletions represent viable mutations. Only
one late-time-point clone (T69 BL 1-9 in Fig. 1) had a
frameshift mutation that was located at amino acid residue
254. None of the other late-time-point clones had in-frame
stop codons or frameshifts in gpl20 that would be part of
defective DNA molecules.
Sequence divergence of SIV variants. The sequence data
were used to quantify variation in the gp120 region of env.
The nucleotide substitution rate was calculated by dividing
the total number of nucleotide substitutions by the total
number of nucleotide bases sequenced and multiplying by a
fraction that accounts for the time of infection. Deletions
were not counted as nucleotide substitutions and were
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subtracted from the total number of nucleotide bases sequenced. For the 10 69-week clones from Mm243-86, there
were 152 nucleotide substitutions per 15,686 total bases
(1.0%) and 123 amino acid changes per 5,228 total residues
4%). The fixation rate of nucleotide substitutions for this
gr(;up of clones was 7.3 x 10-3 per site per year. For the six
93-week clones from Mm243-86, there were 122 nucleotide
substitutions per 9,402 total bases (1.3%) and 102 amino acid
changes per 3,134 total residues (3.3%), and the fixation rate
of nucleotide substitutions was 7.3 x 10-3 per site per year
(Table 1). Nucleotide substitutions thus appeared to accumulate in the virus population over the 24-week time interval
between 69 and 93 weeks in Mm243-86 (Table 2).
For the six 43-week clones from the second animal,
Mm326-87, there were 90 nucleotide substitutions per 9,444
total bases (1.0%) and 70 amino acid changes per 3,148 total
residues (2.2%). The fixation rate of nucleotide substitutions
for Mm326-87 was 1.2 x 10-2 per site per year, which is
approximately 1.6 times higher than the rate for Mm243-86
(Table 1).
Control experiments. Since the SIVmac239 used to infect
Mm243-86 had been propagated in HuT 78 cells for 41 days
before inoculation, we performed a control experiment to
determine the genetic composition of the infecting virus
inoculum. The virus stock used to infect Mm243-86 was
inoculated onto fresh HuT 78 cells, and the virus was grown
for an additional 31 and 55 days. Analysis of five env clones
(Fig. 3) revealed only 16 mutations among the 7,875 bases
sequenced (0.2%) and only 15 amino acid changes per 2,625
total residues (0.6%) (Table 1). This represents an average of
only 3.2 nucleotide substitutions and 3 amino acid changes
per envelope. None of the amino acid changes in clones from
HuT 78 cells were found in clones obtained from the rhesus
monkey. Thus, the vast majority of sequence changes in
clones recovered from the two rhesus monkeys accumulated
during in vivo infection and not during in vitro cultivation of
the virus before inoculation.
To further demonstrate accumulation of changes with time
of in vivo infection, five full-length envelope clones were
obtained from recovered virus at 6 weeks postinfection from
Mm243-86, and the entire gpl20 region was sequenced (Fig.
4). Sequence analysis revealed an average of only 6 nucleotide substitutions and 3.8 amino acid changes per envelope.
A total of 30 mutations were found among the 7,874 bases
sequenced (0.4%), and a total of 19 amino acid changes were
found among the 2,624 residues (0.7%) (Table 1). Two of
these five early-time-point clones had mutations which
would be part of defective molecules; clone T6 V 23-73 had
an in-frame stop codon at residue 350, and clone T6 V 23-85
had a frameshift mutation (deletion of one A) at residue 387
(Fig. 4). Four of the nucleotide substitutions found in these
early-time-point clones from Mm243-86 were also found in
late-time-point clones from the same animal. Although nucleotide substitutions clearly accumulated over the full time
course of infection of Mm243-86, the rate of appearance of
nucleotide substitutions was higher in the 6-week samples
(33 per 1,000 per year) than in the 69- and 93-week samples
(7.3 per 1,000 per year) (Tables 1 and 2).
Preferred nucleotide substitutions. Sequence analysis revealed a strong tendency for G--A and A-*G transitions,
which occurred in 40% (158 of 394) and 30% (120 of 394) of
all nucleotide substitutions, respectively, in clones recovered from the two rhesus monkeys. All other nucleotide
substitutions were found at frequencies of 10% or less,
including the following: 10% T->C, 7% A--C, 5% C-*T, 4%
T-*A, 3% A--T, 1% C-*A, 0.5% T-*G, and 0.5% G--T.
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FIG. 1. Deduced amino acid sequences of late-time-point env clones obtained at 69 and 93 weeks postinfection from rhesus monkey
Mm243-86. T69 and T93 refer to the number of weeks after infection with molecularly cloned SIVmac239. BL refers to blood, LN to lymph
node, and V to cultured cells infected with recovered virus as the source of DNA for PCR amplification and cloning. The numbers 1-9, 1-12,
etc., are individual clone designations. Shown above the 16 postinfection sequences are the sequences of the SIVmac239 clone (30a) and the
HIV-1 lymphadenopathy-associated virus clone (45). Dashes represent amino acid identity; dots represent silent mutations; slashes represent
frameshift mutations. Spaces represent gaps introduced to optimize alignment. Brackets labeled C LOOP and CD4 BINDING DOMAIN refer
to the V3 cysteine loop which is variable in HIV-1 (40) and the CD4 binding domain of HIV-1 (21), respectively. The signal peptide cleavage
site is that of SIV (44). SU, Surface protein (gp12O); TM, transmembrane protein (gp4l) (22).
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---------------- ---------------------------G ---------------------G-----------------------------------------------

-

-------------------------------

-------------G---------------------------------------------G
-------------G -------------------------------G -------------------------------G -----------________
-------------G -------------------------------------------G
-------------G--G-----------------

----------------------- ---G-------.----G ----------------------G -------------------- -------------G ------

----------------

----------------------------------------------------------------------------

-----------------------------

------------------------------

FIG. 1-Continued.

Selection for amino acid changes. Analysis of the types of
nucleotide substitutions found in SU in late-time-point
clones recovered from the two rhesus monkeys revealed a
strong tendency for nucleotide substitutions that changed
the amino acid. Calculation of the proportions of nonsynonymous (amino acid-changing) and synonymous (silent) nucleotide substitutions showed that 81% (295 of 363) were
nonsynonymous, whereas only 19% (68 of 363) were synonymous. The average nonsynonymous nucleotide fixation
rate (6.8 x 103 per site per year) was thus found to be
approximately 4.3 times higher than the average synonymous fixation rate (1.6 x 1O-3 per site per year).
Within the five variable regions, the pattern of nucleotide
substitutions was especially nonrandom. An extremely high

percentage of the mutations in these regions changed the
amino acid (Table 3). Statistically significant differences

found between the observed frequencies of nonsynonsubstitutions and frequencies of nonsynonymous
substitutions expected from random genetic drift. Within the
five variable regions of these clones, a remarkable 182 of 186
nucleotide substitutions changed the amino acid.
To further demonstrate the nonrandom nature of sequence
changes within the five variable regions, the frequencies of
nucleotide substitutions occurring in the first, second, and
third codon positions were determined (Table 4). An extremely high percentage of nucleotide substitutions was
found in the first and second positions. If mutations had
occurred randomly in the variable regions (no in vivo selecwere

ymous
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DIV-1
-RVKEKYQHLNRNGNK
SIVEa c239 M
GCLGNQL
------T43 BL 20-1 T43 DL 20-4
T43 BL 20-7
T43 BL 20-8

T43 BL 20-9 T43 BL 20-10-

16
S

-------

-------------------

-------

Cleavage Site
Signal

DIV-i

SIV-ac239
DL 20-1
DL 20-4
DL 20-7
BL 20-8

T43
T43
T43
T43
T43
T43

WGTM--GILNICSATSK-N---Y --- -V-KE--TT----SDAAY--KZVHNV-A-HA-V-TDPNPQ--VLV---- 91
LIAILLL SVYGIYCTLYVTVrYGVPANRNATIPLFCATKNR DT
WGTTQCLPDNGDYSEVA LNVTZ 73
-------------------------

DL 20-9 ------BL 20-10-------

DIV-1
SIV=ac239

Peptide

--______________,
--------NQ--------------------------__
----------------------------------

--------------

-

__I__
--I--

--------Q-------------------------

N---------------M-

-----

--------Q----------------------Q---------Q--------------------------------Q----------------------Q--

--

N-NM-K-DMV--MH--IIS-WDQ-L------LT---VSLK-TDL

- --I-L---------------L- -----------------N--_ _ __-__

--------------

GNA-NTNSSNTNSS-G0MM04-GEIK

SFDAWNNNVTKQAIEDVWQLrZTSIKPCVKLSPLCITMRCNKSZTDRWGLTKSITTTASTTS

T43 BL 20-1 ---------------------G-----------------N----------T-----AT43 BL 20-4----------------------.--------------------------------------T43 BL 20-7 --------------------- y-----Y--------------N----------T-------T43 BL 20-8 -------------------------------------N---------T43 BL 20-9 ----------------------------------------N----------------A--

T43 BL 20-10-------------V---------------------------------------------AA-

DIV-1
SIVnac239
T43 BL
T43 BL
T43 BL
T43 BL
T43 DL
T43 BL

20-8 --------------------------------------20-9 -------------------------------------20-10---------------------------------------

SIV-ac239

DN

160
144

----------------------

-------------

TS------ 206

VNZTSSCIAQDNCTGLZQEQHISCKFNMTGLKRDKKKEY NET NYSADLVCZQGNNTGNZSRCYNNHCNTSVI

20-1 --------------------------------------20-4 --------T----------------------------G20-7 ---------------------------------------

HIV-1

T43 DL
T43 BL
T43 DL
T43 IL
T43 BL
T43 BL

--SFNISTSIRGKVQKEYAFFYKLDIIPID-D-TS-TL

TTASAKV

---

------------S-----------------

---

--------------D--------------

216

--- ------------S-----------------S-.--------------5----- ------------S-D----------------- --- 0-------D------------------

TQA-P-VSFZP-PIS----A-V-I-K--NKTF-GT-P
-TN-STVQ--HGIRPVV--QLLL--SL--IZVVI- 27 8
QZSCDKHYNDAIRTRYCAPPGYALLRCNDT NYSGFMPKCSKVVVSSCTRMMOSTQTSTNWGYNGTRAZ
NR 285

20-1 ------------------------------

-------------------------------------

20-4

-------------------------------------

-----------------------------

20-7 ------------------------------

-------------------------------------

20-8 ------------20-9 ---------------------------20-10----------T-------------------

-------------------------------------

-------------------------------------

-------------------------------------

C LOOP

HSV-1

SANTT

--AK---VQ--QSVI

IN-T--N-N-RKSIR-QRGP-RA-VTIGKIG- MR--H-NISRA--NAT 346
GLVFHS QPINDRPKQAWCWNGG KWKDA 353

TYIYWHGRDN RThI SLNKYYNLTMKCRRPGNKTVLPVTIMS
SIVmac239
T43 BL 20-1 ----T43 DL 20-4 -----T43 BL 20-7 -T43 BL 20-8 -----Y---- ---- --------------------------T43 DL 20-9 ---------- ---- --------------------------T43 BL 20-10----------

---

-

-

-----------

-----------R-------------R---

-------

-

HIV-1
L--IAS-LREQY-N- KT-IFKQSS-----IVTHSr--G---F--NSTQLr-ST-FNSTNSTZGSNNTZGS 416
SIVeac239
IKZVKQTIVKHPRYTGTNNTDKINLTAPGGGDPEVTFMWTNCRGKVLYCKMNWFLN WVZDRNTANQKPKZQHK 426
T43 BL 20-1 ----------------------------------------T-----L----T43 BL 20-4 ---------------------------------------------------D---- -------T------------------L----T43 DL 20-7 V----------------------------------------------------TRT43 DL 20-8 T-------------------------------------------------------------TT43 BL 20-9 -------------------------------------------------------- -------S----N---T43 DL 20-10--------------------------------------------------------------S---Q---YCD4 BINDING DOMAIN

DIV-1

I

I

DTITL--R-6-F--N-QZ -- -AN-A--IS-QIR-S-NI-G-LLTR-GGNN-NGSZITRPGGGDMRDNWRS--Y6-

491

SIVaac239
ZLGDY 497
RNYVPCHIRQIINTHNKVGKNVYLPPRZGDLTCNSTVTSLIANIDWIDGNQTNITNSAZVAZLYRL
T43 DL 20-1 -----------------------------------------------------------------A---T43 BL 20-4 --*-------------- ----T43 BL 20-7 ---------------------------------------------------------G--------S-T43 BL 20-8
-----------------------------------------------------------------T43 DL 20- 9 -----------------------------------------------------------------T43 DL 20-10 ------------------------------------------------------------------

Cleavage Site SU/TN

-V-K-E-L-V--- lA--R
DIV-I
VVQRZK-A-GI -AL-----GA---T---RKLV SITPIGLAPTDVRYSTTGGTSRNKRGVrVLG VLGrLATAGSANGAAS
SIVaac239
T43 DL 20-1 -------------N----------------------------------T43 DL 20-4 -------------N-------------------- --------------T43 DL 20-7 -------------N----------------------------------T43 DL 20-9 -------------N----------------------------------T43 DL 20-9 ------------- N----A--------------- ---------------T43 DL 20-10-------------N-------------------- ----------------

539

547

FIG. 2. Deduced amino acid sequences of late-time-point env clones obtained at 43 weeks postinfection from rhesus monkey Mm326-87.
The layout of this figure is identical to that of Fig. 1. All six sequences were obtained from cloned DNA from a 43-week PBMC sample.
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TABLE 1. Summary of sequence changes in gp120a
Total no. of:

Name of clone

93-Week clones, Mm243-86
T93 BL 3-18
T93 BL 3-25
T93 BL 3-33
T93 V 8-4
T93 V 8-12
T93 V 8-22
69-Week clones, Mm243-86
T69 BL 1-9
T69 BL 1-12
T69 BL 1-21
T69 LN 2-6
T69 LN 2-17
T69 LN 2-32
T69 V 7-16
T69 V 7-23
T69 V 7-28
T69 V 7-30
6-Week clones, Mm243-86
T6 V 23-72A
T6 V 23-72B
T6 V 23-73
T6 V 23-77
T6 V 23-85
Control clones, Mm243-86
CTL72 0-2
CTL72 0-6
CTL96 00-9
CTL96 00-12
CTL96 00-16
43-Week clones, Mm326-87
T43 BL 20-1
T43 BL 20-4
T43 BL 20-7
T43 BL 20-8
T43 BL 20-9
T43 BL 20-10

Fixation rateb
(nucleotide substitutions per site
per year)

Nucleotide

Nucleotide

Amino acid

Silent

Amino acid

changes

bases

changes

changes

residues

22
20
19
22
20
19

1,575
1,563
1,575
1,563
1,563
1,563

17
19
16
17
17
16

5
1
3
5
3
3

525
521
525
521
521
521

7.8
7.2
6.8
7.9
7.2
6.8

x
x
x
x
x
x

10-3
10-3
10-3
10-3
10-3
10-3

22
19
18
1
11
16
19
15
16
15

1,574
1,563
1,557
1,575
1,554
1,563
1,575
1,575
1,575
1,575

17
16
15
0
7
14
15
12
14
13

5
3
3
1
4
1
4
3
2
2

524
521
519
525
518
521
525
525
525
525

1.1
9.2
8.7
4.8
5.3
7.7
9.1
7.2
7.7
7.2

x
x
x
x
x
x
x
x
x
x

10-2

5
4
7
10
4

1,575
1,575
1,575
1,575
1,574

2
3
5
6
3

3
1
2
4
1

525
525
525
525
524

2.8
2.2
3.9
5.5
2.2

x
x
x
x
x

10-2
10-2
10-2
10-2
10-2

2
2
3
6
3

1,575
1,575
1,575
1,575
1,575

2
2
3
5
3

0
0
0
1
0

525
525
525
525
525

6.4
6.4
7.2
1.4
7.2

x
x
x
x
x

10-3
10-3
10-3

15
14
17
13
13
18

1,575
1,575
1,575
1,569
1,575
1,575

13
9
12
11
11
14

2
5
5
2
2
4

525
525
525
523
525
525

1.2
1.1
1.3
1.0
1.0
1.4

x
x
x
x
x
x

10-2
10-2
10-2
10-2
10-2
10-2

10-3
10-3
i0-4

10-3
10-3
10-3
10-3
10-3

10-3

10-2

10-3

a Deletions were not counted in calculations.
b
Average fixation rates (nucleotide substitutions per site per year) were as follows: for 93-week and 69-week Mm243-86 clones, 7.3 X 10-3; for 6-week
Mm243-86 clones, 3.3 x 10-2; for control Mm243-86 clones, 8.2 x 1O-3; for 43-week Mm326-87 clones, 1.2 x 10-2.

tion), then the mutations should have occurred with relatively equal frequencies in each codon position. Statistically
significant differences were found between the observed and
expected frequencies of mutations in the first, second, and
third base positions in four of the five variable regions.

TABLE 2. Accumulation of changes with time of
infection in vivoa
Avg no. per gpl20

Time of DNA
isolation (wk)

Animal

6
43
69
93

Mm243-86
Mm326-87
Mm243-86
Mm243-86

Nucleotide
substitutions

a Deletions were not counted in calculations.

6.0
15.0
15.2
20.3

Amino acid

changes

3.8
11.7

12.3
17.0

DISCUSSION
One of the key features of SIV- and HIV-induced disease
is the nature of the persistent infection. SIV and HIV, like
other lentiviruses, have a remarkable ability to persist and
eventually induce a chronic, debilitating disease in spite of
an apparently strong host immune response to the virus.
Infected individuals may remain clinically well for years
while maintaining easily detectable humoral and cellular
immune responses, only to succumb eventually to the virus.
The basic mechanisms by which this persistence and chronic
course are achieved are not well understood, but antigenic
variation may be one component of the ability of these
viruses to avoid elimination by the host immune system.
In this report, we have quantified the extensive sequence
variability accumulating in vivo after infection with molecularly cloned virus. We have shown that SIV evolves rapidly
in vivo into a complex mixture of genotypes. The rate at
which nucleotide substitutions become fixed in vivo is determined not only by the mutation rate per replication cycle
and the number of virus replication cycles per unit time but
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HIV-1

SOVmac239
CTL7 2
CTL72
CTL96
CTL96

M

RVKgKYQHLWR"WGWK
GCLGNQL 168

0-2

0-6
00-9 00-12 -

-------------------

CTL96 00-16-

-------

cleavage Site

Signal Peptide
NIV-1

SiVmac239

CTL72 0-2

CTL72

V-KE--TT----SDAAY--VHNV--HA-V-TD
WGTM--GILMICSATKI-W---yWGTTQCLPDNGDTSEVA
LIAILLL SVYGIYCTLYVTVTYGVPAWRNATIPLFCATKNR DT
7

----------------------------------

----- Ir -

0-6 -------CTL96 00-9 CTL96 00-12-------

__

________________

---

___

91
LNVTE 73

__________

_-------------------------------------------------------------

------

----------------------------------

CTL96 00-16-------

GNA-NTNSSNTNSS-GEHMI-GEIK DM
SFDAWNNTVTEQAIEDVWQLTZTSIKPCVKLSPLCITMRCNKSETDRWGLTKSITTTASTTS
_

N-NM-K-DMV--MH--IIS-WDQ-L------T---VSLK-TDL
HIV-1
TTASAKV
SIVmac239
CTL72 0-2 ----------------------- --------------------------------------- -_---CTL72 O0-6
CTL96 00-9 ---------------I----------------CTL96

CTL96

160
14 4

00-12----------------------------I---------------------------------.
00-16----------------------------I---------------------------------I

HIV-1
SIVmac239

TS-------SFNISTSIRGKVQKEYAFFYKLDIIPID-D-TS-TL
VNETSSCIAQDNCTGLEQEQMISCKFNMTGLKRDKKKEY NET WYSADLVCEQGNNTGNESRCYMNHCNTSVI

CTL72
CTL72
CTL96
CTL96 00-12--------------------------------G-----CTL96 00-16--------------------------------G------

0-2 ---------------------- -------------_-0-6 ----------------------------- R--------00- 9 -------------------------------- G ------

HIV-1

---

-------

---------------------------------------------------------------------------------------------------------------------

278
-TN-STVQ--HGIRPV--QLLL--SL--EK'WITQA-P-VSFEP-PIH----A-F-I-K--NKTF-GT-P
NR 285
NYSGFMPKCSKVVVSSCTRMMETQTSTWFGFNGTRAE

QESCDKHYWDAIRFRYCAPPGYALLRCNDT
------------------------------CTL72 0-2
CTL72 0-6 -------- I--------CTL96 00-9-----------------------------------------------------------00-12
CTL96
CTL96 00-16 ------------------------------

SIVmac239

206
216

________-------________-------

-------_-_____-____________________
---------___-______________________

__

------------------------------------

__

------------------------------------------------------------------------C LOOP

I
IN-T--N-N-RKSIR-QRGP-RA-VTIGKIG-

SIVmac239

SANYT
--AK---VQ--QSVZ
TYIYWHGRDN RTII SLNKYYNLTMKCRRPGNKTVLPVTIMS

CTL72 0-2

HIV-1

QPINDRPKQAWCWFGG KNKDA 353

------------------------------------------------- - --- -

------

__-__________-R-

-----------

----------

----

CTL72 0-6 ---------CTL96 00- 9 -CTL96 00-12 ----------

----

----

--------------S-D----------

00-16----------

----

--------------------------

CTL96

L--IAS-LREQF-N-

HIV-1

SIVmac239
CTL72
CTL72
CTL96
CTL96
CTL96

I
MR--H-NISRA--NAT 346

GLVFHS
------

----------------

---------

-

----------------

-----

----------------

KT-IFKQSS ----- IVTHSF--G---F--NSTQLF-ST-FNSTWSTZGSNNTZGS 416

IKEVKQTIVKHPRYTGTNNTDKINLTAPGGGDPEVTFMWTNCRGEFLYCKMNWFLN

WVEDRNTANQKPKZQHK 426

0-2
0-6
-- K------00- 9----------------------------- K------0 0-12----------------------------

-

00-16-----------------------------...K------CD4 BINDING DOMAIN

NIV-1

SIVmac239

CTL72 O0-2
CTL72 0-6
CTL96 00-9
CTL96 00-12

DTT-RKT--Z--A--I-I--IGLT-GNNSIRGGNDWS-K
ELGDY
RNYVPCNIRQIINTWNKVGKNVYLPPRZGDLTCNSTVTSLIANODWIDGNQTNITMSAKVAZLYRL

491
497

-

-

-

CTL96 00-16 ----------------------------------------------------------------------Cleavage Site SU/TM
NOV-i

SlVmac239

CTL72 0-2
CTL72 0-6

VVQKEK-A-GI -AL----GA ---T- -- -K-V-K-K-L-V---K.A--R
KLVEITPIGLAPTDVKRYTTGGTSRNKRGVFrVLG rLGFLATAGSAI4GA-AS
-

539
547

--

CTL96 00-9 --------------------------------------------------CTL96 00-12--------------------------------------------------

CTL96 00-16 -------------------I--- --- - --------FIG. 3. Deduced amino acid sequences of control clones obtained at 72 and 96 days after infection of HuT 78 cells. The layout of this figure
is identical to that of Fig. 1. There is one additional symbol present in this figure; 1, stop codon. Sequences CTL72 0-2 and CTL72 0-6
represent clones 72 days after transfection of HuT 78 cells, whereas sequences CTL96 00-9, CTL96 00-12, and CTL96 00-16 represent clones
96 days after transfection of HuT 78 cells. All five sequences were obtained from clones of Hirt supemnatant DNA.

also by the fitness for survival of the mutants that appear.
The fixation rate of nucleotide substitutions of 8.5 per 1,000
per year in SU (weighted average of late-time-point clones
from Mm243-86 and Mm326-87) is approximately 106 times

higher than that of the average mammalian gene (12, 23) and
for
roughly equivalent to rates that have been reported cell

influenza virus (1, 13) and for type C retroviruses in
culture (6). Amino acid substitutions were fixed at 2.1 per
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H1V-1
SIVmac239 N-RVKZKYQHLWRNGWK
GCLGNQL
T6 V 23-72A------T6 V 23-72B ------T6 V 23-73 ------T6 V 23-77
T6 V 23-85 -

16

-GILVCSATYK-M
---yY ---- V-- -TT- SDAKAY--ZVHNV-A-HA-V-TDPNPQ
DT
LNVTK
SVYGIYCTLYVTVYYGVPAWRNATIPLrCATKNR
WGTTQCLPDNGDYSKVAVLV----

91
73

Cleavage Site
Signal

16V-i
SXVmec239
T6

Peptide

NGTNLIAILLL

23-728-

V
T6 V
T6 V
T6 V

23-7323-7723-5

1KV-1

N-NN-K-DMV--NH--IKS-NDQ-L------T---VSLK-TDL
GNA-NTNSSNTNSS-GKMNJE-G&IK
TTASAKV
SrDAwNNNTVTQAIZDVWQLVZTSIKPCVXLSPLCITMRCNKSITDRNGLTKSITTTASTTS
23-72A--------------------------------------------------------------

SIVmec239

T6 V

T6

1851

160

DN 144

-------

V 23-73

TE V

23-77

-----------------R-----______________

--

T6 V 23-5

3IV-1

SIV=ac239

TG

TS-------SrNISTSIRGKVQKXYArFYKLDISPID-D-TS-TL
NZT NYSADLVCZQGNNTGNZSRCYMNHCNTSVI

VNKTSSCIAQDNCTGLZQZQNISCKrNMTGLKRDKKKKY

206
216

23-72A--------------------------------------V23-72B---------------0--G----

T6 V

---

------------------------------

-----------------

T6 V 23-73
T6 V 23-77
T6 V 23-S

---------------------------------------

3SV-i
SIV-ac239

TQA-P-VSFgP-PIN----A-r-I-x--NXTT-GT-P -TN-STVQ--HGIRPVV--QLLL--SL--KZVVI- 278
QzSCDKxYwDAiRrRYCAPPGYALLRCNDT NYSGFMPRCSKVVVSSCTR)O4TQTSTNrGFNGTRAZ
NR 285

T6 V 23-72A
S6 V 2 3-728

T6

V

23-73

T6 V 23-77
TE V 23-85

----------------------------------- -- -- -------- --- --- ---

---

-------------------------D----

------------------------------------- - --- --- --- - ------------------------_ __ __ _

_

-

C LOOP

3IV-i

SIV-ac239
T6
T6
T6
T6

V
V
V
V
T6 V

--AK---VQ--QSVK IN-T--N-N-RKSXR-QRGP-RA-VTKGKIG- MR--3-NSIRA--NAT 346
TYITYNGRDN RTSI SLNKYYNLTNKCRRPGNKTVLPVTINS GLVFrS QPINDRPKQANCNFGG KNEDA 353
SANYT

23-72A-------K--

----

---------------------------

23-723---------- ----_------------------------23-73 ---------- ---- ---------------------------

z----- ---------------I-------------------Z-----

-----

NI--23-77 ---------- ---- ---------I.---L------------------------L-- ----.-----------23-85
..
z-------------------- --------------------

3KV-i
L--IAS-LRIQV-N- KT-IrKQSS ----- IVTNSr--G--- r--NSTQLV-ST-rNSTNSTZGSNNTZGS 416
SIV-ec2393
KXVKQTIVKHPRYTGTNNTDKINLTAPGGGDPIVTYNTNCRG0FLYCKMNNrLN WVZDRNTANQKPKIQRK 426
---------------T6 V 23-72A----------.--------------------------------------------T6 V 23-723-----------------------------------------------------------------------T6 V 23-73 ---------------------------------------------------------------D-------T6 V 23-77 ---------------------------------------------------------------D-------T6 V 23-5 -------T-------------------------/---------------------- D
CD4 BINDING DOMAIN

I
DTITL--R-K-V- -N-QZ

----A-A--XS-QIR-S-NI-G-LLTR-GGNN-NGSZISFR?GGGDKRDNWRS--YK- 491
3KV-i
ZLGDY 497
SSV-ec239
RNYVPC3IRQIINTNHKVGKNVILPPRIGDLTCNSTVTSLIANIDWIDGNQTNITNSAkVAZLYRL
TG V 23-72A -----------------------------------------------TG V 23-723TG V 23-73
-------------- ----T6 V 23- 77
------------------------------------------------------ _-___-_-___- _-_T6 V 23-a

Cleavage Site SU/TN
-V-K-I-L-V---KA--R
3IV-i
VVQRK-A-G -AL-----GA---T---R- 539
SIVe-c239 KLVITPITGLAPTDVIRYTTGGTSRNKRGVVVLG FLGFLATAGSANGAAS 547
TG V 23-72A ---------------- ---------------TG V 23-72 ---------T6 V 23-73
TG V 23-77
TG V 23- S

FIG. 4. Deduced amino acid sequences of early-time-point env clones obtained at 6 weeks postinfection from rhesus monkey Mm243-86.
The layout of this figure is identical to that of Fig. 1. All five sequences were obtained from clones of Hirt supernatant DNA prepared from
CEM x 174 cells infected with virus recovered at 6 weeks postinfection.

100 per year. This corresponds to 11 amino acid substitutions per gpl20 per year not counting deletions.
The accumulation of changes with time of in vivo infection, the nature of the changes observed, the control experiments, and the clustering of mutations in experimental but
not control clones all argue that our analyses of PCR-derived

clones provide an accurate reflection, both quantitative and
qualitative, of the evolution of sequence changes in vivo.
Furthermore, independent PCR amplifications of blood,
lymph node, and infected cell DNAs from 69-week samples
yielded similar results in terms of the nature and extent of
genetic change.
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TABLE 3. Selection for amino acid changes in five variable
regions in vivo
% (no./total) of nucleotide substitutions
that changed the amino acida
Expected (random
Observed
genetic drift)

Variable
region

Vi
V2
V3d
V4
V5d

97
94
100
100
100

(58/60)
(34/36)
(18/18)
(43/43)
(29/29)

73
78
83
84
83

(44/60)
(28/36)
(15/18)

2

16.70
5.79C
3.60e

(36/43)

8.36b

(24/29)

6.04C

a Late-time-point clones from Mm243-86 and Mm326-87.
b Statistically significant, P < 0.005.
c Statistically significant, P < 0.025.
d
Mm243-86 only.
e Statistically significant, P < 0.100.

All 27 clones recovered from the two rhesus monkeys
were different from each other and differed from the starting
clone. This indicates that authentic, independent clones of
SIVmac239 were analyzed. Comparison of the 27 sequences
also revealed that sequence changes in clones from recovered virus were by and large representative of sequence
changes found in clones from PBMC and lymph node tissue
taken at the same time. Sequences in variable regions 1 and
4 in clones from recovered virus, however, tended to be
more homogeneous than those in clones from blood and
lymph nodes, indicating that there may be cell culture
selection for populations of virus with specific sequences in
certain regions of the envelope gene. Meyerhans et al. (26)
have previously presented evidence for cell culture selection
for individual tat gene variants. Recently, Simmonds et al.
(39) observed no cell culture selection for individual gag
variants.
Although it has been shown for eukaryotic genes that
mutation rates among the four nucleotides are not equal (24),
the percentage of G-*A and A-*G transitions in the SIV
system described in this report seems extraordinarily high.
The high percentage of these transitions might possibly be
related to preferential misincorporation by reverse transcriptase. A G-*A transition could arise through G:T mispairs formed during first-strand synthesis or through A:C
mispairs formed during second-strand synthesis of reverse
transcription. Conversely, an A-*G transition could arise
through A:C mispairs formed during first-strand synthesis or
through G:T mispairs formed during second-strand synthesis. High frequencies of such G:T and A:C mispairs have
TABLE 4. Nonrandom nucleotide substitutions
% (no./total) of nucleotide substitutions that occurred
in the indicated positiona

Variable
region

Observed
First base

Vi
V2
V3C
V4

V5c

54
19
33
66
52

(33/61)
(7/37)

(6/18)
(29/44)
(15/29)

Second base

26
76
44
25
48

(16/61)
(28/37)

(8/18)
(11/44)
(14/29)

Expected

(random nuThird base

20
5
22
9
0

(12/61)
(2/37)

(4/18)
(4/44)
(0/29)

X2

cleotide
substitutions)
33
33
33
33

(20/61)
(12/37)

(6/18)
(15/44)
33 (10/29)

a Late-time-point clones from Mm243-86 and Mm326-87.
bStatistically significant, P < 0.005.
c Mm243-86 only.

12.24b
31.74b
1.33
22.21b

14.10b

been reported in studies with the HIV-1 reverse transcriptase (30, 31, 46). There may be some structural basis for
these mutations in terms of the conformations of particular
types of mismatches as seen by reverse transcriptase in
copying natural DNA sequences (32). Goodenow et al. (8a)
previously reported a strong preference for G -* A base
substitutions in HIV-1. The deamination of methylated cytosine residues (C--T transition) in integrated SIV molecules
is another possible mechanism for the high frequency of
G->A transitions (3); however, since methylated C residues
in eukaryotic DNA occur almost exclusively at 5'-CG-3'
dinucleotides (5, 9) and since there are only eight such CG
dinucleotides within the 1,575 bp of SU, methylation is not a
likely explanation. Since the base composition of SU is 35%
A, 26% T, 22% G, and 17% C, the preponderance of G-*A
and A--G transitions cannot be explained by a high percentage of G and A in the viral RNA. Finally, misincorporation
by Taq polymerase is not a likely explanation for the high
percentage of G->A and A--G transitions based on previous
experiments on Taq fidelity (43).
In our study of SIV env variation, we have observed not
only a high percentage of G-*A and A--G transitions but
also a statistically significant proportion of nucleotide substitutions occurring in the first and second codon positions
(Table 4). The observed pattern of nucleotide substitutions
might therefore be related to selection of preferred amino
acid substitutions in the SIV envelope glycoprotein. A full
81% of the nucleotide substitutions in SU in late-time-point
clones from two rhesus monkeys changed the amino acid.
The fixation rate of nonsynonymous nucleotide substitutions
(6.8 x 1i0 per site per year) was found to be approximately
4.3 times higher than the fixation rate of synonymous mutations (1.6 x 10- per site per year). Within the five variable
regions, a remarkable 98% (182 of 186) of the nucleotide
substitutions changed the amino acid, and statistically significant differences between observed frequencies and frequencies expected from random genetic drift were found
(Table 3). The difference in nonsynonymous versus synonymous fixation rates in the SIVmac env gene contrasts
markedly with rates for eukaryotic genes. Li et al. (25), for
example, have shown that the nonsynonymous mutation rate
for eukaryotic genes is only one-fifth the synonymous mutation rate. Quite clearly, this usual predominance of synonymous mutations results from severe limitations on the
numbers of amino acid changes that will still allow optimal
protein function. Like cellular genes, the HIV-1 gag gene
shows a bias toward synonymous mutations (39). These
observations, together with the lack of focal accumulation of
substitutions in the variable regions of SU in virus passaged
for 3 months in cell culture, suggest that there are strong
selective forces for amino acid changes in certain segments
of the SIV envelope gene in vivo.
Five variable regions have been identified in late-timepoint clones from Mm243-86 and Mm326-87. Four of these
five variable regions of SIV (Vl, V2, V4, and V5) correspond
to variable regions Vl, V2, V4, and V5 of HIV-1 (40) (Fig.
5). Variable regions 1 and 2 of SIV do not correspond to any
functional domains or epitopes identified in the HIV-1 system. Variable region 3 of SIV is located in a region which
corresponds to a weak cytotoxic T-lymphocyte epitope of
HIV-1 (41). Variable region 4 of SIV, located immediately
upstream of the region corresponding to the HIV-1 CD4
binding domain (21), does not correspond to any known
functional domains or epitopes in the HIV-1 envelope.
Finally, variable region 5 of SIV gpl20, located immediately
downstream of the region corresponding to the HIV-1 CD4
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FIG. 5. Summary of variable regions of HIV-1 and SIVmac in
SU. Variable regions Vl, V2, V4, and V5 of SIVmac correspond to
variable regions Vl, V2, V4, and V5, respectively, of HIV-1.

binding domain, corresponds to a previously reported neutralization epitope of HIV-1 (15). The V5 region of SIV is the
only variable region that corresponds to any of the HIV-1
neutralization epitopes identified to date.
One surprising result from our study was that the region
corresponding to the variable V3 cysteine loop of HIV-1 was
not found to be variable in SIVmac239; this region was found
to be quite conserved among the 27 clones analyzed. The
variable V3 cysteine loop of HIV-1 is believed to be a major
target for neutralizing antibodies (8b, 33). RP135, a 24amino-acid peptide from this region (located between amino
acid residues 300 and 337 in Fig. 1), blocked fusion inhibition
of antisera raised against the entire HIV-1 env or against the
central region of env and also blocked the activity of serum
from a chimpanzee infected with HIV-1 "'B (33). It will be
interesting to see whether this region is a major neutralization epitope of SIV, as it is in HIV-1. In addition to being a
neutralizing determinant, the V3 cysteine loop of HIV-1 has
also been reported to contain a major cytotoxic T-lymphocyte epitope (41).
The selective pressures that contribute to the pattern of
variation have not been defined. However, the host immune
response is likely to be one important driving force. Whether
the SIV variable regions identified in this study are targets of
humoral or cell-mediated immunity and whether sequence
variation in these regions allows the virus to evade ongoing
antibody and T-cell responses are important questions for
future investigation. Recently, Haigwood et al. (11) presented strong evidence for the role of at least three HIV-1
gpl20 variable regions in recognition by neutralizing antibodies. Variable regions may influence neutralizing antibody
recognition in direct ways, by serving as target epitopes (33),
or in indirect ways, by changing three-dimensional or conformational epitopes from a distance (17, 29, 47). The system
and reagents defined in this report will allow us to investigate
in exquisite detail the significance of sequence variation for
recognition by neutralizing antibodies. Sera from these animals have been stored at numerous time points after infection, and the variant envelope genes were cloned in such a
way as to allow easy replacement into cloned virus.
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